SlideShare a Scribd company logo
4
Most read
6
Most read
17
Most read
BASICS OF MEDICAL STATISTICS
SHARED FROM TINY NAIR (CSI UPDATE 2016)
KEYWORDS
• PROBABILITY: (P)
• SAMPLE SIZE
• EFFECT SIZE
• ODDS AND ODDS RATIO
• RISK AND RISK RATIO
• STANDARD DEVIATION
• HOW TO USE SD INTELLIGENTLY
• CONFIDENCE INTERVAL
• HOW TO INTERPRET A CLINICAL TRIAL
• CALCULATE NNT
• TYPES OF TRIAL
PROBABILITY
• Probability is an indicator of how much of the data can happen just by chance. p value of less
than (<) 0.5 p <0.5 = 5/10 = ½ indicates that there is 50% chance that the result may be
happening just because of a chance
• p = 0.05 = 5/100 = 1/20
• To be statistically significant look for a p value of at least less than 0.05
• p <0.05 Statistically significant
• p <0.01 Highly significant
• p <0.001 Very highly significant
• Always look at the sample size /confidence interval (CI) before giving a judgment on p value
alone
SAMPLE & EFFECT SIZE
• The value of p is inversely proportional to effect size and sample size
• This means if we are testing the effects of a new blood pressure medicine is reducing
blood pressure by 20 mm Hg, but was tested in only 100 patients, the p value may be
significant but the sample size is too small to be significant. In similar lines, a drug
reducing blood pressure by merely 1 mm Hg may return a significant p value, when
tested in 1 million populations but the effect size is too small to be worthwhile
statistically
• To avoid statistical error, today the statistician calculates the minimum sample
size that would be required to show a difference of results depending on the
prevalence of the event rate in the natural course of the disease in the population
being studied
ODDS
• The term Odds means a disease or effect happening versus not happening
• Supposing that 10 out of 100 patients of acute myocardial infarction would die, the
odds are 10 will die and 90 will live. So, the Odds are 10/90 = 0.11 (Happens/Not
Happen) Now a medical paper says that there is a new drug ABC shows benefit in
reducing death rate of myocardial infarction. On being treated with the new drug, only
2 out of 100 acute myocardial infarction cases died. This means 2 dies and 98 live. So
Odds for this new treatment are 2/98 = 0.02
ODD RATIO
• Odds Ratio = control odds/Treatment Odds = 0.11/0.02 = 5.5
• This means treatment with this new drug reduces chance of death by 5.5 times
RISK AND RISK RATIO
• Risk is a similar term that means disease or effect out of the entire population. In
the same example of the heart attack above, the risk of death is 10 out of 100
(not 10/90 as in odds) Risk of death in MI 10/100 = 0.10 (Happens/Total) Similarly
risk after being administered ABC has a risk of 2/100 = 0.02
RISK RATIO
• Risk ratio = 0.10/0.02 = 5 (very close to odds ratio)
• In most cases, odds ratio and risk ratio is close
• Now consider, unlike the example of myocardial infarction, a disease has a
mortality of 90% (90 out of 100 die). In such a scenario, the odds would be 90/10
(died 10 survived) returning a value of odds of 9, while the risk ratio would be
90/100 = 0.9. So, dichotomy between odds and risk indicate high event rate in
control group and this may corrupt a study
STANDARD DEVIATION
• Any physiological parameter will have variation from people to people
• If we take sufficient number of people and plot their values, they tend to follow a
normal or nominal distribution (a Bell-shaped curve)
• The central line in the curve is the mean (akin to arithmetic average)
• As we go farther away from the mean, the degree of deviation (from mean)
increases
• One standard deviation (1 SD) covers 68.2% of data spread from mean. 2SD
covers more, up to 95.4% data and 3 SD covers almost a whooping 99.7% data
EXAMPLE OF S.D
• Serum cholesterol in a population of a town of 8,000 people . Most people have a
mean cholesterol of 200 mg (Central Line), while some as low as 100 and as high
as 300. Standard deviation is 25 mg of cholesterol. This means if we look at ± 1
standard deviation the value would range from 175 to 225. One standard
deviation constitutes of 68.2% of the population data in any normal distribution
(5456 people) the entire dark group. If we take two standard deviation it covers
the cholesterol values from 150 to 250 covering 95.4% of the population (7,632
people). The dark and light group. Three standard deviation covers 99.7% of the
population from the cholesterol level of 100–300 (7,976 of 8,000). This means
three standard deviation practically cover entire data set.=The whole shaded area.
Basics of medical statistics
CONFIDENCE INTERVAL
• Confidence interval = 0.83 (CI 0.88–0.98) The upper value is below 1. So, it is
statistically significant. However, clinical significance of a value is considered only
when it is below 0.85. So, in this case, it is statistically significant, but clinically not
significant
• Confidence interval = 0.78 (CI 0.76–0.97) Here the upper value is below 1, while the
lower one is below 0.85. Hence, it is statistically significant and may be clinically
significant
• Confidence interval = 0.78 (CI 0.57–1.12) Here the value wraps around 1, hence
statistically not significant. However, since the lower value is below 0.85, it may still be
clinically significant. In such cases, a repeat trial is indicated.
• Confidence interval = 0.59 (CI 0.43 – 0.76) In this case, both the upper and lower
values are below 0.85, so it is statistically as well as clinically significant
Basics of medical statistics
EXAMPLE
• Journal Report New Drug XYZ Reduces Heart Failure Mortality by 20%
• Study with a new drug XYZ’ for heart failure.
• 5/1,000 patients died with standard care at end of 1 year=0.5%
• 4/1,000 patients on XYZ died at end of 1 year=0.4%
• Absolute risk reduction (ARR) – the real thing = 0.5 – 0.4 = 0.1%
• Relative risk reduction (RRR) = 0.1/0.5 = 20%
• The logical next step would be to check for p value, NNT and CI Look for p value
•
CONTD……EXAMPLE
• Accept if p < 0.05
• Many noninferiority trials try to show weather the drug or treatment is “not worse”
compared to the present gold standard, but do not ask whether it is better or not. This
means it is checking one end (single tail) of the standard bell curve and not both the
ends (double tails). A single tailed trial needs a higher p value to be significant (at least
p, 0.01)
• Ask for confidence interval, if wraps around unity
• Reject it (e.g. 0.56–1.23 goes to junk)
• Enquire pre-specified endpoints.
NNT
• Calculate NNT NNT is number needed to treat to prevent one event (let one
Death) NNT is calculated by dividing 100/APR = 100/0.1 = 1000 So, you need to
treat 1,000 patients to prevent one death
• NNT is significant (acceptable) if more than 50
• Here ,it is 1,000, so not significant.
TYPES OF TRIAL
• Observational studies: prevalence of a disease or its complications
• Interventional studies: Randomized and placebo- controlled for guideline
formation
TYPES OF TRIALS
CONCLUSION
• A step-by step approach to look for
• ARR
• p value
• NNT
• CI
• Can simply data
BIBLIOGRAPHY
1. Harris M, Taylor G, Dunitz M. Medical Statistics Made Easy. London and New
York: Martin Dunitz; 2003.
2. Magnello E, Loon BV. Statistics, A graphic Guide. Icon Books, UK.
3. Mayer D. Essential Evidenced Based Medicine, Dan Mayer, Cambridge
medicine, 2nd edn. US: Cambridge University Press; 2009.
4. Nair T. Medical Statistics and Clinical Trials, 1st edn. Wiley Blackwell. 5. Sanjay
K, Diamond G. Trial and error: how to avoid commonly encountered limitations
of published clinical trials, J Am Coll Cardiol. 2010;55:415-27.
DO YOU KNOW WHAT DOES CITY MEAN ?
• C:Cutting
• I:Innocent
• T:Trees
• Y:Yatra

More Related Content

What's hot (20)

PPTX
NNT: Number Needed to Treat
Dr. Shubhi Saxena
 
PPTX
Odds ratio
Madhur Bora
 
PPTX
Sample size calculation for cohort studies
Subhashini N
 
PDF
Intent-to-Treat (ITT) Analysis in Randomized Clinical Trials
Mike LaValley
 
PDF
Survival analysis & Kaplan Meire
Dr Athar Khan
 
PDF
Randomised Controlled Trial, RCT, Experimental study
Dr Lipilekha Patnaik
 
PPTX
Superiority, non-inferiority, equivalence studies - what is the difference?
simonledinek
 
PDF
Measures of association
IAU Dent
 
PPTX
Roc curves
Prayas Gautam
 
PPTX
ODDS RATIO AND RELATIVE RISK EVALUATION
Kanhu Charan
 
PDF
Sensitivity, specificity and likelihood ratios
Chew Keng Sheng
 
PPTX
Interim analysis in clinical trials (1)
ADITYA CHAKRABORTY
 
PDF
Biases in meta-analysis
Rizwan S A
 
PPTX
Agreement analysis
Dhritiman Chakrabarti
 
PPTX
Sample size calculation
Swati Singh
 
PPT
2. Tools to calculate samplesize
Azmi Mohd Tamil
 
PPTX
Odds ratios (Basic concepts)
Tarekk Alazabee
 
PPTX
Study design
AhadRehman
 
PPSX
Relative and Atribute Risk
Tauseef Jawaid
 
NNT: Number Needed to Treat
Dr. Shubhi Saxena
 
Odds ratio
Madhur Bora
 
Sample size calculation for cohort studies
Subhashini N
 
Intent-to-Treat (ITT) Analysis in Randomized Clinical Trials
Mike LaValley
 
Survival analysis & Kaplan Meire
Dr Athar Khan
 
Randomised Controlled Trial, RCT, Experimental study
Dr Lipilekha Patnaik
 
Superiority, non-inferiority, equivalence studies - what is the difference?
simonledinek
 
Measures of association
IAU Dent
 
Roc curves
Prayas Gautam
 
ODDS RATIO AND RELATIVE RISK EVALUATION
Kanhu Charan
 
Sensitivity, specificity and likelihood ratios
Chew Keng Sheng
 
Interim analysis in clinical trials (1)
ADITYA CHAKRABORTY
 
Biases in meta-analysis
Rizwan S A
 
Agreement analysis
Dhritiman Chakrabarti
 
Sample size calculation
Swati Singh
 
2. Tools to calculate samplesize
Azmi Mohd Tamil
 
Odds ratios (Basic concepts)
Tarekk Alazabee
 
Study design
AhadRehman
 
Relative and Atribute Risk
Tauseef Jawaid
 

Similar to Basics of medical statistics (20)

PPTX
Understanding clinical trial's statistics
Magdy Khames Aly
 
PPTX
Biostatistics.pptx
SagarAGavankar
 
PDF
Biostatistics and epidemiology 01stats20
nokwazimhlongo02
 
PPTX
Epidemological methods
Kundan Singh
 
PPTX
Overview of different statistical tests used in epidemiological
shefali jain
 
PPT
Statistics basics for oncologist kiran
Kiran Ramakrishna
 
PDF
introduction to biostatistics in clinical trials
stopit2404
 
PDF
introduction to biostatistics in clinical trials
stopit2404
 
PPT
Medical statistics Basic concept and applications [Square one]
Tarek Tawfik Amin
 
PPT
25_Anderson_Biostatistics_and_Epidemiology.ppt
PriyankaSharma89719
 
PPTX
Dr. RM Pandey -Importance of Biostatistics in Biomedical Research.pptx
PriyankaSharma89719
 
PPTX
Application of statistical tests in Biomedical Research .pptx
Halim AS
 
PPT
COM 301 INFERENTIAL STATISTICS SLIDES.ppt
danielayo912
 
PPTX
Module7_RamdomError.pptx
ShafaatHussain20
 
PDF
Lecture by Professor Imre Janszky about random error.
EPINOR
 
PDF
Introduction to small samples binomial inference
CollinsMusera1
 
PDF
Difference of Proportions, Relative Risk, Odds Ratio
CollinsMusera1
 
PPT
Critical Appriaisal Skills Basic 1 | May 4th 2011
NES
 
PPTX
Analysis 101
Brian Wells, MD, MS, MPH
 
PPTX
Bio-Statistics in Bio-Medical research
Shinjan Patra
 
Understanding clinical trial's statistics
Magdy Khames Aly
 
Biostatistics.pptx
SagarAGavankar
 
Biostatistics and epidemiology 01stats20
nokwazimhlongo02
 
Epidemological methods
Kundan Singh
 
Overview of different statistical tests used in epidemiological
shefali jain
 
Statistics basics for oncologist kiran
Kiran Ramakrishna
 
introduction to biostatistics in clinical trials
stopit2404
 
introduction to biostatistics in clinical trials
stopit2404
 
Medical statistics Basic concept and applications [Square one]
Tarek Tawfik Amin
 
25_Anderson_Biostatistics_and_Epidemiology.ppt
PriyankaSharma89719
 
Dr. RM Pandey -Importance of Biostatistics in Biomedical Research.pptx
PriyankaSharma89719
 
Application of statistical tests in Biomedical Research .pptx
Halim AS
 
COM 301 INFERENTIAL STATISTICS SLIDES.ppt
danielayo912
 
Module7_RamdomError.pptx
ShafaatHussain20
 
Lecture by Professor Imre Janszky about random error.
EPINOR
 
Introduction to small samples binomial inference
CollinsMusera1
 
Difference of Proportions, Relative Risk, Odds Ratio
CollinsMusera1
 
Critical Appriaisal Skills Basic 1 | May 4th 2011
NES
 
Bio-Statistics in Bio-Medical research
Shinjan Patra
 
Ad

More from https://aiimsbhubaneswar.nic.in/ (20)

PPTX
LEFT MAIN BIFURCATION STENTING EBC 2024.pptx
https://aiimsbhubaneswar.nic.in/
 
PPTX
COMPLETE ATRIOVENTRICULAR HEART BLOCK.pptx
https://aiimsbhubaneswar.nic.in/
 
PPTX
Willens's syndrome.pptx
https://aiimsbhubaneswar.nic.in/
 
PPTX
Intensive care of congenital heart disease.pptx
https://aiimsbhubaneswar.nic.in/
 
PPTX
Management of Hypetension.pptx
https://aiimsbhubaneswar.nic.in/
 
PDF
CRISPR and cardiovascular diseases.pdf
https://aiimsbhubaneswar.nic.in/
 
PDF
Pacemaker Pocket Infection After Splenectomy
https://aiimsbhubaneswar.nic.in/
 
PDF
Piccolo Duct Occluder.pdf
https://aiimsbhubaneswar.nic.in/
 
PPTX
MISPLACED ECG LEADS.pptx
https://aiimsbhubaneswar.nic.in/
 
PDF
A Case of Device Closure of an Eccentric Atrial Septal Defect Using a Large D...
https://aiimsbhubaneswar.nic.in/
 
PPTX
Arrythmia-IV.pptx
https://aiimsbhubaneswar.nic.in/
 
PPTX
Arrythmia-III.pptx
https://aiimsbhubaneswar.nic.in/
 
PPTX
Arrythmia-II.pptx
https://aiimsbhubaneswar.nic.in/
 
PPTX
Arrythmia-I.pptx
https://aiimsbhubaneswar.nic.in/
 
PDF
Trio of Rheumatic Mitral Stenosis, Right Posterior Septal Accessory Pathway a...
https://aiimsbhubaneswar.nic.in/
 
PPTX
Anticoagulation therapy during pregnancy
https://aiimsbhubaneswar.nic.in/
 
PDF
Coronary guidewire
https://aiimsbhubaneswar.nic.in/
 
PDF
Intracoronary optical coherence tomography
https://aiimsbhubaneswar.nic.in/
 
PDF
A roadmap for the human development
https://aiimsbhubaneswar.nic.in/
 
LEFT MAIN BIFURCATION STENTING EBC 2024.pptx
https://aiimsbhubaneswar.nic.in/
 
COMPLETE ATRIOVENTRICULAR HEART BLOCK.pptx
https://aiimsbhubaneswar.nic.in/
 
Willens's syndrome.pptx
https://aiimsbhubaneswar.nic.in/
 
Intensive care of congenital heart disease.pptx
https://aiimsbhubaneswar.nic.in/
 
Management of Hypetension.pptx
https://aiimsbhubaneswar.nic.in/
 
CRISPR and cardiovascular diseases.pdf
https://aiimsbhubaneswar.nic.in/
 
Pacemaker Pocket Infection After Splenectomy
https://aiimsbhubaneswar.nic.in/
 
Piccolo Duct Occluder.pdf
https://aiimsbhubaneswar.nic.in/
 
MISPLACED ECG LEADS.pptx
https://aiimsbhubaneswar.nic.in/
 
A Case of Device Closure of an Eccentric Atrial Septal Defect Using a Large D...
https://aiimsbhubaneswar.nic.in/
 
Trio of Rheumatic Mitral Stenosis, Right Posterior Septal Accessory Pathway a...
https://aiimsbhubaneswar.nic.in/
 
Anticoagulation therapy during pregnancy
https://aiimsbhubaneswar.nic.in/
 
Intracoronary optical coherence tomography
https://aiimsbhubaneswar.nic.in/
 
A roadmap for the human development
https://aiimsbhubaneswar.nic.in/
 
Ad

Recently uploaded (20)

PPTX
molecular pharmaceutics m pharm ppt.pptx
abdulubed0701
 
PDF
How Does Conolidine Offer Natural Alternative Pain Relief?
conolidineweb
 
PPTX
OMODELE MORENIKE PRESENTATION NAVDOC-4.pptx
Omodelemorenike
 
PPT
Natural-Resources UNIT -1st EVS ( B.pharm 2nd sem)
surya singh
 
PDF
SCHIZOPHRENIA (ANTIPSYCHOTIC DRUGS)..pdf
SATENDRAPRADHAN1
 
PDF
what types of cancer by sayyam health centre
miansayyam360
 
PPTX
2.5 Role of Nasal & Pharyngeal Cavity in Voice Production (aqsa mehsood).pptx
Aqsa Mehsood
 
PDF
nocturnal enuresis presentation By Dr Harish kalasua
harishkalasua327
 
PPTX
Esophagus Debate NCTRT vs NACT by Dr Kanhu Charan Patro
Kanhu Charan
 
PDF
Urinary tract infections (UTI) - AMBOSS.pdf
Abbas Mushtaq Ali
 
PPTX
Regulatory Aspects of Herbal and Biologics in INDIA.pptx
Aaditi Kamble
 
PPTX
Beyond Compliance Embracing Quality by Design (QbD) for Next-Generation Pharm...
Dr. Smita Kumbhar
 
PPTX
Hepatopulmonary syndrome presentation .pptx
medicoanil9
 
PPT
The Second Coming of Finite Therapy in CLL: Making Informed Treatment Decisio...
PVI, PeerView Institute for Medical Education
 
PDF
Chronic kidney disease (CKD) - AMBOSS.pdf
Abbas Mushtaq Ali
 
PPTX
JULY 2025 Oncology Cartoons by Dr Kanhu Charan Patro
Kanhu Charan
 
PPTX
11 .Neurosurgery (part.1) cranial surgery.pptx
Bolan University of Medical and Health Sciences ,Quetta
 
PPTX
Guide to Antenatal care in obstetrics for undergraduates
aniyakhan948
 
PDF
The Evolving Landscape of Fibrosing Interstitial Lung Diseases: Equipping Cli...
PVI, PeerView Institute for Medical Education
 
PPTX
Case Study Report on Renal Cell Carcinoma with Demyelinating Polyneuropathy
CourtneyPiltaver
 
molecular pharmaceutics m pharm ppt.pptx
abdulubed0701
 
How Does Conolidine Offer Natural Alternative Pain Relief?
conolidineweb
 
OMODELE MORENIKE PRESENTATION NAVDOC-4.pptx
Omodelemorenike
 
Natural-Resources UNIT -1st EVS ( B.pharm 2nd sem)
surya singh
 
SCHIZOPHRENIA (ANTIPSYCHOTIC DRUGS)..pdf
SATENDRAPRADHAN1
 
what types of cancer by sayyam health centre
miansayyam360
 
2.5 Role of Nasal & Pharyngeal Cavity in Voice Production (aqsa mehsood).pptx
Aqsa Mehsood
 
nocturnal enuresis presentation By Dr Harish kalasua
harishkalasua327
 
Esophagus Debate NCTRT vs NACT by Dr Kanhu Charan Patro
Kanhu Charan
 
Urinary tract infections (UTI) - AMBOSS.pdf
Abbas Mushtaq Ali
 
Regulatory Aspects of Herbal and Biologics in INDIA.pptx
Aaditi Kamble
 
Beyond Compliance Embracing Quality by Design (QbD) for Next-Generation Pharm...
Dr. Smita Kumbhar
 
Hepatopulmonary syndrome presentation .pptx
medicoanil9
 
The Second Coming of Finite Therapy in CLL: Making Informed Treatment Decisio...
PVI, PeerView Institute for Medical Education
 
Chronic kidney disease (CKD) - AMBOSS.pdf
Abbas Mushtaq Ali
 
JULY 2025 Oncology Cartoons by Dr Kanhu Charan Patro
Kanhu Charan
 
11 .Neurosurgery (part.1) cranial surgery.pptx
Bolan University of Medical and Health Sciences ,Quetta
 
Guide to Antenatal care in obstetrics for undergraduates
aniyakhan948
 
The Evolving Landscape of Fibrosing Interstitial Lung Diseases: Equipping Cli...
PVI, PeerView Institute for Medical Education
 
Case Study Report on Renal Cell Carcinoma with Demyelinating Polyneuropathy
CourtneyPiltaver
 

Basics of medical statistics

  • 1. BASICS OF MEDICAL STATISTICS SHARED FROM TINY NAIR (CSI UPDATE 2016)
  • 2. KEYWORDS • PROBABILITY: (P) • SAMPLE SIZE • EFFECT SIZE • ODDS AND ODDS RATIO • RISK AND RISK RATIO • STANDARD DEVIATION • HOW TO USE SD INTELLIGENTLY • CONFIDENCE INTERVAL • HOW TO INTERPRET A CLINICAL TRIAL • CALCULATE NNT • TYPES OF TRIAL
  • 3. PROBABILITY • Probability is an indicator of how much of the data can happen just by chance. p value of less than (<) 0.5 p <0.5 = 5/10 = ½ indicates that there is 50% chance that the result may be happening just because of a chance • p = 0.05 = 5/100 = 1/20 • To be statistically significant look for a p value of at least less than 0.05 • p <0.05 Statistically significant • p <0.01 Highly significant • p <0.001 Very highly significant • Always look at the sample size /confidence interval (CI) before giving a judgment on p value alone
  • 4. SAMPLE & EFFECT SIZE • The value of p is inversely proportional to effect size and sample size • This means if we are testing the effects of a new blood pressure medicine is reducing blood pressure by 20 mm Hg, but was tested in only 100 patients, the p value may be significant but the sample size is too small to be significant. In similar lines, a drug reducing blood pressure by merely 1 mm Hg may return a significant p value, when tested in 1 million populations but the effect size is too small to be worthwhile statistically • To avoid statistical error, today the statistician calculates the minimum sample size that would be required to show a difference of results depending on the prevalence of the event rate in the natural course of the disease in the population being studied
  • 5. ODDS • The term Odds means a disease or effect happening versus not happening • Supposing that 10 out of 100 patients of acute myocardial infarction would die, the odds are 10 will die and 90 will live. So, the Odds are 10/90 = 0.11 (Happens/Not Happen) Now a medical paper says that there is a new drug ABC shows benefit in reducing death rate of myocardial infarction. On being treated with the new drug, only 2 out of 100 acute myocardial infarction cases died. This means 2 dies and 98 live. So Odds for this new treatment are 2/98 = 0.02
  • 6. ODD RATIO • Odds Ratio = control odds/Treatment Odds = 0.11/0.02 = 5.5 • This means treatment with this new drug reduces chance of death by 5.5 times
  • 7. RISK AND RISK RATIO • Risk is a similar term that means disease or effect out of the entire population. In the same example of the heart attack above, the risk of death is 10 out of 100 (not 10/90 as in odds) Risk of death in MI 10/100 = 0.10 (Happens/Total) Similarly risk after being administered ABC has a risk of 2/100 = 0.02
  • 8. RISK RATIO • Risk ratio = 0.10/0.02 = 5 (very close to odds ratio) • In most cases, odds ratio and risk ratio is close • Now consider, unlike the example of myocardial infarction, a disease has a mortality of 90% (90 out of 100 die). In such a scenario, the odds would be 90/10 (died 10 survived) returning a value of odds of 9, while the risk ratio would be 90/100 = 0.9. So, dichotomy between odds and risk indicate high event rate in control group and this may corrupt a study
  • 9. STANDARD DEVIATION • Any physiological parameter will have variation from people to people • If we take sufficient number of people and plot their values, they tend to follow a normal or nominal distribution (a Bell-shaped curve) • The central line in the curve is the mean (akin to arithmetic average) • As we go farther away from the mean, the degree of deviation (from mean) increases • One standard deviation (1 SD) covers 68.2% of data spread from mean. 2SD covers more, up to 95.4% data and 3 SD covers almost a whooping 99.7% data
  • 10. EXAMPLE OF S.D • Serum cholesterol in a population of a town of 8,000 people . Most people have a mean cholesterol of 200 mg (Central Line), while some as low as 100 and as high as 300. Standard deviation is 25 mg of cholesterol. This means if we look at ± 1 standard deviation the value would range from 175 to 225. One standard deviation constitutes of 68.2% of the population data in any normal distribution (5456 people) the entire dark group. If we take two standard deviation it covers the cholesterol values from 150 to 250 covering 95.4% of the population (7,632 people). The dark and light group. Three standard deviation covers 99.7% of the population from the cholesterol level of 100–300 (7,976 of 8,000). This means three standard deviation practically cover entire data set.=The whole shaded area.
  • 12. CONFIDENCE INTERVAL • Confidence interval = 0.83 (CI 0.88–0.98) The upper value is below 1. So, it is statistically significant. However, clinical significance of a value is considered only when it is below 0.85. So, in this case, it is statistically significant, but clinically not significant • Confidence interval = 0.78 (CI 0.76–0.97) Here the upper value is below 1, while the lower one is below 0.85. Hence, it is statistically significant and may be clinically significant • Confidence interval = 0.78 (CI 0.57–1.12) Here the value wraps around 1, hence statistically not significant. However, since the lower value is below 0.85, it may still be clinically significant. In such cases, a repeat trial is indicated. • Confidence interval = 0.59 (CI 0.43 – 0.76) In this case, both the upper and lower values are below 0.85, so it is statistically as well as clinically significant
  • 14. EXAMPLE • Journal Report New Drug XYZ Reduces Heart Failure Mortality by 20% • Study with a new drug XYZ’ for heart failure. • 5/1,000 patients died with standard care at end of 1 year=0.5% • 4/1,000 patients on XYZ died at end of 1 year=0.4% • Absolute risk reduction (ARR) – the real thing = 0.5 – 0.4 = 0.1% • Relative risk reduction (RRR) = 0.1/0.5 = 20% • The logical next step would be to check for p value, NNT and CI Look for p value •
  • 15. CONTD……EXAMPLE • Accept if p < 0.05 • Many noninferiority trials try to show weather the drug or treatment is “not worse” compared to the present gold standard, but do not ask whether it is better or not. This means it is checking one end (single tail) of the standard bell curve and not both the ends (double tails). A single tailed trial needs a higher p value to be significant (at least p, 0.01) • Ask for confidence interval, if wraps around unity • Reject it (e.g. 0.56–1.23 goes to junk) • Enquire pre-specified endpoints.
  • 16. NNT • Calculate NNT NNT is number needed to treat to prevent one event (let one Death) NNT is calculated by dividing 100/APR = 100/0.1 = 1000 So, you need to treat 1,000 patients to prevent one death • NNT is significant (acceptable) if more than 50 • Here ,it is 1,000, so not significant.
  • 17. TYPES OF TRIAL • Observational studies: prevalence of a disease or its complications • Interventional studies: Randomized and placebo- controlled for guideline formation
  • 19. CONCLUSION • A step-by step approach to look for • ARR • p value • NNT • CI • Can simply data
  • 20. BIBLIOGRAPHY 1. Harris M, Taylor G, Dunitz M. Medical Statistics Made Easy. London and New York: Martin Dunitz; 2003. 2. Magnello E, Loon BV. Statistics, A graphic Guide. Icon Books, UK. 3. Mayer D. Essential Evidenced Based Medicine, Dan Mayer, Cambridge medicine, 2nd edn. US: Cambridge University Press; 2009. 4. Nair T. Medical Statistics and Clinical Trials, 1st edn. Wiley Blackwell. 5. Sanjay K, Diamond G. Trial and error: how to avoid commonly encountered limitations of published clinical trials, J Am Coll Cardiol. 2010;55:415-27.
  • 21. DO YOU KNOW WHAT DOES CITY MEAN ? • C:Cutting • I:Innocent • T:Trees • Y:Yatra